Targeting tumor suppressor gene co‐mutations in <i>EGFR</i> ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification
K
Krishna S. Gunturu
(Hartford HealthCare Cancer Institute Hartford Connecticut USA)
H
Hina Khan
(The Warren Alpert Medical School of Brown University Providence Rhode Island USA)
G
Gilberto de Lima Lopes
(Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine Miami Florida USA)
Article Details
Volume / Issue
Vol. 76, Issue 2
Published
March 01, 2026
ISSN
0007-9235
Publisher
Wiley
Authors (3)
K
Krishna S. Gunturu
Hartford HealthCare Cancer Institute Hartford Connecticut USA
H
Hina Khan
The Warren Alpert Medical School of Brown University Providence Rhode Island USA
G
Gilberto de Lima Lopes
Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine Miami Florida USA
Related Articles from this Journal
Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates
Xia Wu, Heather Landau et al.
May 2026
10.3322/caac.70092
Screening for colorectal cancer
May 2026
10.3322/caac.70087
Correction to “Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases”
May 2026
10.3322/caac.70093
Blood tests for colorectal cancer—Hype ahead of evidence?
Gloria D. Coronado, David A. Lieberman
May 2026
10.3322/caac.70088
Medullary thyroid carcinoma and <i>RET</i> molecular testing: A virtual tumor board on clinical decision‐making
Lucas Kallas‐Silva, Victor Alexandre dos Santos Valsecchi et al.
May 2026
10.3322/caac.70086